Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly ...
A team of scientists is investigating a new type of antibody, which stimulates the immune system to target cancer cells an ...
This drug works by combining the antibody trastuzumab with a drug called emtansine. Trastuzumab works by binding to HER2 proteins that are found on the cells of HER2-positive breast cancer.
AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...
Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim ...
Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer ...
Frazier Life Sciences has launched Callio Therapeutics with $187 million in series A funds and a HER2-targeted dual-payload ...
First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-⍺ (FR⍺) and ZW171, a ...
WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and ...
The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...
1d
News Medical on MSNNew antibody reduces tumor growth in treatment-resistant breast and ovarian cancersA new type of antibody which stimulates the immune system to target cancer cells slows tumour growth, according to new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results